News article

Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis. With the widespread availability of elexacaftor/tezacaftor/ivacaftor (ETI) and dramatic improvement in respiratory symptoms, attention is turning to the role of therapies designed to maintain lung health. Some early studies have reported a reduced bacterial burden in the lungs after ETI, though results are easily confounded by the reduction in sputum samples and the impact on chronic P.  aeruginosa infection remains unknown.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Source Type: research